Optimi Health Corp . a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers the companies have confirmed their intent to proceed with a Phase I clinical trial application that will document the safety of the Optimi’s natural psilocybin biomass .
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received an acknowledgement letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a pilot study of SLS-005 for the treatment of patients with Alzheimer s .
Awakn Life Sciences Corp. a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, today is reporting its financial results and business highlights for the three and nine months ended October 31, 2021. All results are reported under International Financial Reporting Standards and in Canadian dollars, unless otherwise specified.Anthony Tennyson, Chief Executive Officer of Awakn .
NeonMind Biosciences Inc. an integrated drug development and wellness company, is pleased to announce that President and CEO, Rob Tessarolo, is scheduled to participate in a panel discussion at Lift & Co. Expo s new Psychedelics Business Summit, on November 19, 2021, in Toronto. The panel entitled, "Business Leaders: Committing to Business Strategies and Approaches that Will Benefit Patients - and Investors, will .